For emerging pharma and biotech teams, few distinctions matter more or get blurred more often than the difference between quality assurance and quality control. Both are essential. Both are scrutinized during inspections. And yet, many fast-moving drug development teams treat them as interchangeable, or worse, skip the infrastructure for one entirely until an auditor shows up.
This isn't just a terminology problem.
Conflating QA and QC leads to real operational gaps: missing audit trails, undefined ownership of corrective actions, SOPs that describe testing steps as process controls, and training records that don't trace back to document versions. These are exactly the kinds of gaps that slow clinical programs down, trigger agency findings, and erode investor confidence.
Understanding how quality assurance and quality control differ, and how they work together, is foundational to building a quality framework that can survive inspection and scale with your programs. This guide breaks it down clearly, with practical context for the life sciences teams that need it most.
What Is Quality Assurance?
Quality assurance is a proactive, process-oriented discipline. Its purpose is to prevent quality problems before they occur by establishing the systems, processes, and standards that govern how work gets done across an organization.
In practice, QA is concerned with the how. How documents get authored and approved. How vendors get qualified. How deviations get escalated, and how training gets delivered and verified. It operates continuously throughout the product lifecycle rather than at a single checkpoint, which is what separates it conceptually from QC.
Core QA activities in life sciences include:
- SOP authoring, approval, and version control: establishing controlled procedures that govern every regulated activity
- Training management: ensuring all personnel are trained on current versions of applicable SOPs before performing regulated tasks
- Internal audits and vendor qualification: assessing whether your organization and your CROs, labs, and suppliers are operating in compliance with applicable standards
- CAPA management: documenting and tracking corrective and preventive actions to address root causes of quality events
- Change control: managing the review and approval of any changes to validated processes, systems, or documents
- Quality event management: capturing and investigating deviations, non-conformances, and complaints
QA is typically owned by quality leadership and is inherently cross-functional. It touches regulatory affairs, clinical operations, manufacturing, and IT. Its regulatory grounding includes ICH Q10 (Pharmaceutical Quality System), GxP guidelines, and FDA 21 CFR Part 11, which governs electronic records and signatures used in regulated environments.
What Is Quality Control?
Quality control is reactive and product-focused. Where QA asks "are we doing things the right way?", QC asks "did this output meet the required standard?"
QC activities happen at defined checkpoints, after a process has run, and are designed to detect defects or non-conformances in a finished product, batch, document, or deliverable. It is not about building systems; it is about checking results.
In life sciences, QC shows up across several functions:
- Analytical and laboratory testing: testing drug substance, drug product, or raw materials against predefined specifications
- Batch record review: verifying that manufacturing processes were executed correctly and that all required steps were completed and documented
- Document QC review: checking submission documents, clinical study reports, or regulatory filings for accuracy, completeness, and formatting before they go out
- In-process testing: sampling and testing at defined stages of a manufacturing process to catch issues before a batch is complete
- TMF completeness review: verifying that all required trial master file documents are present, approved, and properly filed
QC is often associated with laboratory or manufacturing teams in drug product development. But in the regulatory context, it also applies to the review steps that happen before documents are submitted to health authorities. Its regulatory grounding includes ICH Q7 (Good Manufacturing Practice for Active Pharmaceutical Ingredients) and broader GMP standards.
QA vs QC: Side-by-Side
| Quality Assurance (QA) | Quality Control (QC) | |
|---|---|---|
| Focus | Process | Product / Output |
| Approach | Proactive | Reactive |
| Goal | Prevent defects | Detect defects |
| When it happens | Throughout the lifecycle | At defined checkpoints |
| Who owns it | Quality leadership, cross-functional | Lab, manufacturing, regulatory ops |
| Example activities | SOP management, audits, CAPA, training | Lab testing, batch review, document QC |
| Regulatory basis | ICH Q10, GxP, 21 CFR Part 11 | ICH Q7, GMP standards |
The most important takeaway from this comparison is that QA and QC are not competing approaches. They are complementary. A robust quality framework needs both.
QA without QC leaves you with well-documented processes that no one is actually verifying at the output level. QC without QA means you are catching defects after the fact without the process infrastructure to prevent them from recurring. One builds the foundation; the other checks the work.
Why the Distinction Matters in Drug Development
The FDA, EMA, MHRA, and other health authorities expect both QA and QC to be clearly defined, documented, and operational within your quality system. During an inspection, investigators are not just looking at test results. They are evaluating whether your organization has the processes, controls, and culture to consistently produce quality outcomes. That requires evidence of a working QA framework, not just a stack of QC data.
When teams conflate QA and QC, several predictable problems emerge.
SOPs that describe testing procedures get miscategorized as quality system documents, leaving reviewers confused about scope and ownership. Corrective actions get initiated without a clear CAPA framework to manage them, so root causes go unresolved. Training records exist, but they are not linked to specific document versions, making it impossible to demonstrate that personnel were trained on current procedures at the time they performed a task.
These are not hypothetical edge cases. They are the kinds of findings that appear in FDA Warning Letters and EMA inspection reports, particularly for smaller sponsors who built quality infrastructure reactively rather than proactively.
Consider a biotech company entering Phase II with a strong scientific team but no formal QA function. They have lab notebooks, some SOPs in a SharePoint folder, and a CRO managing their trial master file. When a regulatory authority requests documentation of their quality system ahead of a site inspection, they scramble to produce evidence of controlled procedures, training records, and deviation management. None of it was systematically maintained. The result is an inspection finding that delays the program, not because the science was flawed, but because the quality infrastructure was not there.
A validated, purpose-built quality management system removes the burden of building this infrastructure from scratch. It ensures that both QA activities and QC workflows are captured, traceable, and inspection-ready from the start. That is exactly the problem Kivo is designed to solve for emerging life sciences teams.
QA and QC Across the Drug Development Lifecycle
Understanding where QA and QC show up at each stage of development helps teams allocate responsibility and build the right infrastructure at the right time.
Preclinical
QA establishes the foundational document control framework: SOP library, controlled document management, training curricula. QC reviews study data and lab outputs against predefined acceptance criteria.
This is the stage where investing in QA infrastructure pays the biggest dividends. It is far cheaper to build a compliant SOP framework before your first IND than to retrofit one during clinical trials, when everyone is already stretched thin.
IND / CTA Filing
QA ensures that the processes governing study conduct are in place and documented. QC reviews the submission documents themselves, checking for completeness, accuracy, and format compliance before they go to health authorities. A document QC checklist at this stage can catch errors that would otherwise trigger agency questions and slow the review clock by months.
Clinical Trials
This is where both disciplines are most active simultaneously. QA manages vendor and CRO qualification, ongoing training, protocol deviation management, and CAPA tracking. QC reviews TMF completeness, verifies data accuracy, and checks clinical study reports against source data.
For sponsors working with multiple CROs across multiple sites, keeping QA and QC activities coordinated and documented in a single system stops being a nice-to-have and becomes operationally essential.
NDA / BLA Submission
QA ensures the full audit trail is intact and that all required quality records support the submission package. QC conducts final document reviews and checks submission packages for structural and content compliance with eCTD requirements. Missing or inconsistent documentation at this stage can trigger deficiency letters and delay approval by months or years.
Post-Approval
QA manages change control and CAPA for any post-approval changes to manufacturing processes, labeling, or quality systems. QC continues to monitor product quality through ongoing batch testing and stability programs. As product volumes scale, the rigor of both QA and QC systems must scale alongside them.
As teams move through these stages, the volume and complexity of QA and QC documentation grows substantially. Managing it manually through spreadsheets, email threads, and disconnected file systems becomes increasingly untenable and increasingly risky.
The Role of a QMS in Supporting Both QA and QC
A Quality Management System is the operational infrastructure that makes both QA and QC work at scale.
It is the system of record for your controlled documents, your training history, your quality events, your audits, and your corrective actions. Without one, you are relying on individual discipline and institutional memory to maintain compliance. That works until it does not, and in a regulated environment the consequences of failure are severe.
A purpose-built QMS for life sciences should enable your team to:
- Author, review, approve, and version-control SOPs and other controlled documents with a full audit trail
- Manage training curricula and link training completion directly to specific document versions
- Capture and track quality events, including deviations, non-conformances, and complaints, through resolution
- Manage CAPA workflows with defined owners, timelines, and effectiveness checks
- Plan and document internal audits and vendor assessments
- Generate real-time reports on document status, training completion, open quality events, and upcoming renewals
This is precisely what Kivo QMS is designed to do. Built on a Part 11 compliant Document Management Platform and pre-validated out of the box, Kivo gives growing life sciences teams the quality infrastructure they need without the six-figure price tag or months-long implementation timeline that legacy systems require. The platform supports SOP authoring and approval workflows, training management, quality event tracking, vendor audits, and reporting, all in a single intuitive workspace.
What makes Kivo particularly well-suited for teams managing both QA and QC activities is the integration across the broader platform. Kivo's QMS, DMS, RIM, and eTMF are built as components of the same system rather than patched-together acquisitions. That means quality teams get end-to-end visibility across submission documents, trial master files, and regulatory activities, without the data silos that make crossfunctional QA oversight so difficult in legacy environments.
Common Mistakes Emerging Pharma Teams Make
Even well-intentioned quality teams make predictable mistakes when QA and QC are not clearly defined and operationalized.
Treating QA and QC as the same role. When one person is responsible for both writing the SOPs and QC-checking the output against them, you lose the independence that makes each function meaningful. These roles do not have to be held by different people in small organizations, but they do need to be performed as distinct, documented activities.
Managing controlled documents in SharePoint or shared drives. These tools were not designed for regulated document management. They lack the version control, access management, audit trails, and electronic signature capabilities required by 21 CFR Part 11 and EU Annex 11. Using them feels practical in the short term and creates significant risk over time.
No training records linked to document versions. Regulators expect you to demonstrate not just that personnel were trained, but that they were trained on the version of the SOP that was current at the time they performed the task. Generic training logs do not satisfy this requirement.
No formal quality event management process. Deviations and non-conformances happen in every program. What regulators want to see is that you captured them, investigated them, and implemented corrective actions. If quality events are tracked in email or a spreadsheet, that evidence trail is fragile and often incomplete.
Waiting until pre-inspection to build QA infrastructure. This is the most costly mistake of all. Building a quality system under inspection pressure is expensive, stressful, and almost always results in gaps. The right time to implement a QMS is before your first IND, not six months before your NDA.
How to Build a QA/QC Framework That Scales
For emerging life sciences teams, building a quality framework that can grow with your programs comes down to a few foundational decisions made early.
Start with controlled document management. Before anything else, you need a system that can store, version, and control access to your SOPs, policies, and work instructions in a compliant, auditable way. This is the backbone of your QA infrastructure, and everything else is built on top of it.
Define ownership explicitly. Identify who is responsible for QA activities (process governance, audits, CAPA) and who is responsible for QC review at each stage of your program. Write those responsibilities into your quality system documents so they are not subject to interpretation when things get busy.
Link training to documents from the start. Every time an SOP is approved or revised, your training management process should automatically generate a training requirement for applicable personnel. This linkage is essential for audit readiness and one of the first things an inspector will look for.
Integrate vendor and audit management into your QA framework early. Your CROs, labs, and suppliers are extensions of your quality system. Qualifying them formally and documenting that qualification in your QMS gives you the evidence trail you need when regulators ask about third-party oversight. They will ask.
Choose a validated, pre-built system over a homegrown solution. Implementing a purpose-built QMS like Kivo takes weeks rather than months and eliminates the burden of system validation from your team. The time savings, cost savings, and reduction in compliance risk make this an easy decision for most emerging life sciences teams once they see what the alternative actually costs.
Frequently Asked Questions
Is quality assurance or quality control more important in pharma?
Neither is more important. Both are required. QA and QC serve fundamentally different purposes, and regulatory authorities expect evidence of both operating within your quality system.
That said, many emerging teams underinvest in QA infrastructure early, which creates compounding compliance risk as programs scale. If you had to prioritize one first, build your QA framework: the process controls, SOP library, and training system. The QC checkpoints are only as strong as the processes behind them.
What is an example of QA vs QC in clinical trials?
Here is a clear one. Your QA team authors and approves a protocol deviation management SOP, trains all study staff on it, and tracks compliance through periodic audits. When a deviation actually occurs at a site, your QC process kicks in: reviewing the deviation report, checking that it was captured accurately, and verifying that the CAPA was implemented correctly.
QA built the process. QC verified the output. Both are necessary; neither replaces the other.
Do small pharma or biotech companies need a formal QMS?
Yes, and the earlier the better. Regulators do not apply different standards based on company size. A sponsor entering their first IND is subject to the same GxP and 21 CFR Part 11 requirements as a large pharmaceutical company.
The difference is that small teams often cannot afford the enterprise QMS platforms built for big pharma. That is exactly why Kivo exists: to give emerging life sciences teams a validated, Part 11 compliant QMS at a price point that makes sense for companies at any stage of development.
What does 21 CFR Part 11 have to do with QA and QC?
21 CFR Part 11 is the FDA regulation governing electronic records and electronic signatures in regulated environments. It applies to any system used to create, modify, maintain, archive, retrieve, or transmit records required by FDA regulations. That includes your QMS, your document management system, and your eTMF.
Both QA and QC activities that are documented electronically must be conducted in a Part 11 compliant system to be defensible in an inspection. If your SOPs live in an unvalidated SharePoint site and your training logs live in a spreadsheet, you have a Part 11 problem whether you know it or not.
How do I know if my quality system is inspection-ready?
Ask yourself three questions. Can you pull a complete audit trail for any controlled document in under five minutes? Can you demonstrate, for any given team member, exactly what they were trained on and when? Can you show the full lifecycle of any quality event from identification through CAPA closure?
If the answer to any of those is "not easily," your quality system has gaps worth addressing before an inspector asks the same questions in person.
Can a QMS handle both QA and QC workflows?
A purpose-built QMS handles QA workflows natively: controlled documents, training, audits, CAPA, quality events. QC activities that involve document review, such as reviewing a clinical study report or TMF document before approval, are also supported through the document management and workflow features of a platform like Kivo.
For laboratory QC workflows involving instrument data and batch records, you may need an integrated LIMS in addition to your QMS, depending on your manufacturing stage. The key is choosing a QMS that integrates cleanly with the rest of your tech stack rather than one that creates its own silo.
Conclusion
Quality assurance and quality control are not the same thing, but they are equally essential to a functional, inspection-ready quality system. QA builds the infrastructure that prevents quality failures from happening. QC verifies that outputs meet the standards QA has defined. Together, they give regulators and your own leadership team confidence that your development programs are well-governed and your data can be trusted.
For emerging life sciences teams, the challenge is not understanding the distinction intellectually. It is building the operational infrastructure to support both disciplines without breaking the budget or grinding program timelines to a halt.
A validated, purpose-built QMS removes most of that burden, giving your quality team the tools they need to manage controlled documents, training, audits, CAPA, and quality events in one compliant, intuitive system. Kivo's QMS was designed specifically for growing pharmaceutical and biotech teams who need enterprise-grade quality infrastructure without the enterprise-grade complexity and cost. Pre-validated, Part 11 compliant, and deployable in weeks rather than months, it is the quality foundation your programs deserve from day one.
Schedule a demo to see how Kivo QMS supports both quality assurance and quality control in one integrated platform.
